JNJ-42165279
Sponsors
Janssen Pharmaceutica N.V., Belgium, Janssen Research & Development, LLC
Conditions
AnxietyAutism Spectrum DisorderDepressive DisorderHealthyPhobic Disorders
Phase 1
A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of JNJ-42165279 in Healthy Male Participants
CompletedNCT02065739
Start: 2014-01-31End: 2014-03-31Updated: 2014-04-23
A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand 11C-MK-3168 and the Blocking of the Retention of the Ligand in the Human Brain by JNJ-42165279
CompletedNCT02169973
Start: 2014-02-28End: 2014-07-31Updated: 2015-09-28
A Single and Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of JNJ-42165279 in Healthy Japanese Male Participants
CompletedNCT03564379
Start: 2018-06-12End: 2018-08-13Updated: 2025-04-27
Phase 2
A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder
CompletedNCT02432703
Start: 2015-06-11End: 2018-08-09Updated: 2025-04-29
An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress
CompletedNCT02498392
Start: 2015-10-07End: 2019-02-04Updated: 2025-04-29
A Study to Investigate the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Participants With Autism Spectrum Disorder
CompletedNCT03664232
Start: 2018-11-07End: 2022-10-28Updated: 2025-04-23